Cleveland HeartLab Adds New Patent to its Extensive Intellectual Property Position for the Myeloperoxidase (MPO) Test, a Powerful Biomarker for Inflammation and its Role in Major Cardiac Events

CLEVELAND, Feb. 22, 2017 /PRNewswire/ -- Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that a new patent for Myeloperoxidase (MPO) testing has been issued, Patent…
Continue Reading »